Pharmacogenetic‐Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017

This study aimed to determine to which extent data on potential pharmacogenetic‐pharmacokinetic (PG‐PK) interactions are provided to, and assessed by, the European Medicines Agency (EMA) in novel drug marketing authorization applications (MAAs), and whether regulatory assessment of PG‐PK interaction...

Descripción completa

Detalles Bibliográficos
Autores principales: Maliepaard, Marc, Toiviainen, Timi, De Bruin, Marie L., Meulendijks, Didier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484984/
https://www.ncbi.nlm.nih.gov/pubmed/32236952
http://dx.doi.org/10.1002/cpt.1834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484984/
https://www.ncbi.nlm.nih.gov/pubmed/32236952
http://dx.doi.org/10.1002/cpt.1834

Ejemplares similares